Skyland Analytics' Market Share Climbs As Drug And COVID-19 Vaccine Developers Look To Accelerate Delivery Through Digital Transformation

Leader in cloud-based process information management and collaboration software sees increased adoption of Skyland PIMS® as bio/pharma companies look for data systems that can be deployed rapidly to support accelerated drug development and manufacturing programs.

Skyland Analytics, a leader in cloud-based data analytics and data management software solutions for clinical and commercial-stage drug companies, reports that adoption of its PIMS™ software has surged during the COVID-19 outbreak as life science companies seek cloud-based tools that support accelerated development, clinical and manufacturing schedules, and drive collaboration among remote internal and external teams. This growth comes amidst continued travel and workplace restrictions that create increased challenges on the already complex drug supply chain.

• Several key benefits are driving adoption of Skyland PIMS by bio/pharma and vaccine developers at all stages of the product life cycle:
• Purpose-built technology for drug sponsors and their manufacturing partners to manage operations and collaborate remotely with just a web browser.
• Elimination of time-consuming, error-prone spreadsheets with a centralized, digital data spine brings scattered data sources together and accelerates go-to-market activities with confidence.
• Meets FDA guidelines for the design and testing of software used to support GMP drug manufacturing.
• Provides intuitive, compliant workflows and auto-generated analytics that accelerate business, quality, and regulatory reporting (e.g., CPV, APR/PQR, CMC).
• Rapid SaaS deployment, and no custom-coding, enables users to be up and running in a matter of hours without heavy IT infrastructure or lengthy training.

Speeds tech transfer and onboarding with contract manufacturers (CMOs).
“Life science companies who are able to maintain productivity and product quality during crises gain a competitive advantage,” said Robert Di Scipio, CEO of Skyland Analytics. He continued, “Our team are leaders in this field and are proud of our ability to help customers foster collaboration on the cloud among a geographically distributed workforce, monitor supply chains, and streamline product and process data management with higher data integrity.”

About Skyland Analytics
Skyland Analytics streamlines drug product and process data management by offering cloud-based software solutions that ensure Part 11-compliance, data transparency and data integrity throughout the product lifecycle and supply chain. With deep expertise in manufacturing, IT systems, data analytics and product quality, Skyland is uniquely positioned to provide life science organizations producing clinical and/or commercial-stage drug products innovative technology that accelerates commercialization and meets evolving business and regulatory demands. For more information, visit www.SkylandAnalytics.net.